ATE407671T1 - Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen - Google Patents

Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen

Info

Publication number
ATE407671T1
ATE407671T1 AT04731575T AT04731575T ATE407671T1 AT E407671 T1 ATE407671 T1 AT E407671T1 AT 04731575 T AT04731575 T AT 04731575T AT 04731575 T AT04731575 T AT 04731575T AT E407671 T1 ATE407671 T1 AT E407671T1
Authority
AT
Austria
Prior art keywords
medication
prevention
treatment
production
eating disorders
Prior art date
Application number
AT04731575T
Other languages
English (en)
Inventor
Vidal Merce
Mataro Andaluz
Constansa Frigola
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200301077A external-priority patent/ES2219181B1/es
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Application granted granted Critical
Publication of ATE407671T1 publication Critical patent/ATE407671T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
AT04731575T 2003-05-09 2004-05-07 Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen ATE407671T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301077A ES2219181B1 (es) 2003-05-09 2003-05-09 Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias.
ES200301782 2003-07-28

Publications (1)

Publication Number Publication Date
ATE407671T1 true ATE407671T1 (de) 2008-09-15

Family

ID=33436171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04731575T ATE407671T1 (de) 2003-05-09 2004-05-07 Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen

Country Status (13)

Country Link
US (1) US20050065202A1 (de)
EP (1) EP1626715B1 (de)
JP (1) JP2006525972A (de)
AR (1) AR044275A1 (de)
AT (1) ATE407671T1 (de)
AU (1) AU2004237420B2 (de)
BR (1) BRPI0410189A (de)
CA (1) CA2524682A1 (de)
DE (1) DE602004016491D1 (de)
ES (1) ES2313002T3 (de)
NO (1) NO20055492L (de)
RU (1) RU2005138147A (de)
WO (1) WO2004098588A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2222832B1 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2222830B1 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2222829B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2246721B1 (es) * 2004-08-10 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos.
EP1632491A1 (de) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituierte indol-verbindungen und deren verwendung als modulatoren des 5-ht6 rezeptors
EP1676841A1 (de) * 2004-12-30 2006-07-05 Esteve Laboratorios Dr. Esteve S.A. Substituierte Indazolsulfonamid- und 2,3-Dihydroindolyl-Sulfonamidverbindungen, deren Herstellung und Verwendung in Medikamenten
CN101374808B (zh) * 2006-01-24 2011-05-25 伊莱利利公司 孕酮受体的吲哚磺酰胺调节剂
EP1902733A1 (de) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Kombination von einem NMDA Rezeptorligand und einer Verbindung mit 5-HT6 Rezeptor-Affinität
EP1953153A1 (de) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituierte Sulfonamide für die Behandlung von Wahrnehmungsstörungen bzw. Ernährungserkrankungen
EP1953141A1 (de) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Aryl-substituierte Sulfonamide für die Behandlung von Wahrnehmungsstörungen oder Ernährungskrankheiten
EP2053052A1 (de) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Verfahren zur Herstellung von 6-substituiertem Imidazo[2,1-b]thiazol-5-sulfonylhalogenid
DE102008019838A1 (de) * 2008-04-19 2009-12-10 Boehringer Ingelheim International Gmbh Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
EP2149573A1 (de) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Substituierte Indolsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699918B1 (fr) * 1992-12-30 1995-03-17 Pf Medicament Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
FR2712591B1 (fr) * 1993-11-19 1996-02-09 Pf Medicament Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
FI963571L (fi) * 1994-03-11 1996-11-08 Lilly Co Eli Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi
AU702322B2 (en) * 1995-03-20 1999-02-18 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
US6060642A (en) * 1997-08-15 2000-05-09 The Regents Of The University Of California Serotonin 5-HT6 receptor knockout mouse
EP1373203A1 (de) * 2001-03-29 2004-01-02 Bristol-Myers Squibb Company Cyclopropylindolderivate als selektive serotoninwiederaufnahmehemmer
EP1401812B1 (de) * 2001-06-15 2006-06-28 F. Hoffmann-La Roche Ag 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor
EP1411925A1 (de) * 2001-08-03 2004-04-28 PHARMACIA & UPJOHN COMPANY 5-arylsulfonyl-indole mit 5-ht6 rezeptor-affinität
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
RU2005138147A (ru) 2007-06-27
AR044275A1 (es) 2005-09-07
EP1626715B1 (de) 2008-09-10
JP2006525972A (ja) 2006-11-16
ES2313002T3 (es) 2009-03-01
NO20055492L (no) 2005-11-21
AU2004237420B2 (en) 2009-04-09
BRPI0410189A (pt) 2006-05-23
DE602004016491D1 (de) 2008-10-23
US20050065202A1 (en) 2005-03-24
AU2004237420A1 (en) 2004-11-18
WO2004098588A1 (en) 2004-11-18
CA2524682A1 (en) 2004-11-18
EP1626715A1 (de) 2006-02-22

Similar Documents

Publication Publication Date Title
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
NL300933I2 (nl) Letermovir
ATE280580T1 (de) Verwendung von annexin-modulatoren zur herstellung eines medikaments zur behandlung und/oder vorbeugung von arthritis und arthritischen erkrankungen
EP1572075A4 (de) Verfahren zur behandlung von krankheiten in verbindung mit abnormaler kinasewirkung
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
DE60317586D1 (de) Verfahren zur Herstellung von mehrschichtigen, halbleitenden Nanopartikeln und und die nach diesem Verfahren erhaltenen mehrschichtigen, halbleitenden Nanopartikel
EP1851237A4 (de) Pharmazeutische zusammensetzungen zur behandlung oder prävention von knochenerkrankungen
ATE440099T1 (de) Herstellung und anwendung von tetrahydropyrrolo ä3, 2-cüpyridin-4-onderivaten zur behandlung von obesitas und psychiatrischen und neurologischen erkrankungen
DE602004016491D1 (de) Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen
DE69916632D1 (de) Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
ATE381929T1 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
ATE344262T1 (de) 2-heteroarylcarbonsäureamide
PL1608811T3 (pl) Wyrób wielowarstwowy i sposób jego wytwarzania
DE602005014145D1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
WO2006026204A3 (en) Novel gamma-lactams as beta-secretase inhibitors
ATE526958T1 (de) Acetyl-l-carnitin für die vorbeugung und/oder behandlung von peripheren neuropathien hervorgerufen durch thalidomid
DE60230455D1 (de) Natürliche verbindung für die behandlung von diabetes, deren herstellung und verwendung
ATE465986T1 (de) Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck
WO2007053495A3 (en) Compounds useful as antagonists of ccr2
EP1791423A4 (de) Zusammensetzungen und verfahren für die behandlung von hyperproliferativen hautkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties